Trial · NCT07909733
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT
NCT07909733, Phase 1, Not yet recruiting, University of Wisconsin, Madison
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT. Trials, record NCT07909733. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07909733
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT
- NCT number
- NCT07909733
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 27 participants, estimated
- Lead sponsor
- University of Wisconsin, Madison
- Conditions
High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation, Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Primary Myelofibrosis (PMF), Intermediate-risk Myelodysplastic Syndrome, High-risk Myelodysplastic Syndrome (MDS), Very High Risk Myelodysplastic Syndrome, Secondary Myelofibrosis
- Interventions
- imetelstat
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum tolerated dose (MTD) of imetelstat | 1 year | MTD defined as the highest dose level at which \< 2 of 6 subjects experience a dose- limiting toxicity (DLT). |
| Secondary | Incidence of adverse events | 2 years | Adverse events as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. |
| Secondary | Rate of non-relapse mortality (NRM) | 2 years | NRM is defined as the duration between the date of allo-SCT and the date of patient death due to reasons other than relapse. |
| Secondary | Rate of relapse | 2 years | Relapse is defined by the commonly used, well established criteria for each disease. For acute leukemia, relapse is defined by the reappearance of \>5% myeloblasts in the BM not attributable to BM regeneration or to any other cause. For other conditions including myelofibrosis, CML, and MDS, relapse will be defined by hematologic, morphologic, cytogenetic, or molecular recurrence in the clinical setting that is pertinent for that disease. |
| Secondary | Progression-free survival (PFS) | 2 years | PFS is defined from the time of allo-SCT to disease relapse or death from any cause. Patients alive and progression free will be censored at the date of the last negative bone marrow. |
| Secondary | Overall survival (OS) | 2 years | OS is defined from the time of allo-SCT to the date of death from any cause. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07909733
GET https://conductscience.org/api/trials/v1/NCT07909733/registered